| 1 | 21470995 | The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. | J Clin Endocrinol Metab | 2011 Jun |
2 |
| 2 | 21540237 | Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. | Clin Cancer Res | 2011 Jun 15 |
2 |
| 3 | 21606412 | Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. | J Clin Oncol | 2011 Jul 1 |
8 |
| 4 | 21613405 | VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. | Cancer Res | 2011 Jul 15 |
1 |
| 5 | 21926191 | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. | Mol Cancer Ther | 2011 Dec |
16 |
| 6 | 22146228 | Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). | Drugs Today (Barc) | 2011 Nov |
8 |
| 7 | 22343387 | Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. | Curr Opin Oncol | 2012 May |
6 |
| 8 | 22367858 | Computer-aided quantitative bone scan assessment of prostate cancer treatment response. | Nucl Med Commun | 2012 Apr |
1 |
| 9 | 23082047 | c-Met in pancreatic cancer stem cells: therapeutic implications. | World J Gastroenterol | 2012 Oct 14 |
1 |
| 10 | 23104465 | Cabozantinib for the treatment of advanced medullary thyroid cancer. | Adv Ther | 2012 Nov |
3 |
| 11 | 23169517 | Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. | J Clin Oncol | 2013 Feb 1 |
2 |
| 12 | 23319867 | Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. | Onco Targets Ther | 2013 |
1 |
| 13 | 23337762 | Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. | Cancer J | 2013 Jan-Feb |
1 |
| 14 | 23337763 | From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. | Cancer J | 2013 Jan-Feb |
1 |
| 15 | 23484006 | Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. | PLoS One | 2013 |
7 |
| 16 | 23533264 | Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. | Cancer Discov | 2013 Jun |
3 |
| 17 | 23553848 | A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. | Clin Cancer Res | 2013 Jun 1 |
1 |
| 18 | 23661005 | The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. | Cell Death Dis | 2013 May 9 |
5 |
| 19 | 23705946 | In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. | Thyroid | 2013 Dec |
12 |
| 20 | 23817317 | The changing landscape in metastatic castration-resistant prostate cancer. | Curr Opin Support Palliat Care | 2013 Sep |
1 |
| 21 | 23856028 | Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. | Cancer Lett | 2013 Oct 1 |
2 |
| 22 | 23991695 | RET fusion gene: translation to personalized lung cancer therapy. | Cancer Sci | 2013 Nov |
1 |
| 23 | 24002501 | Cabozantinib in progressive medullary thyroid cancer. | J Clin Oncol | 2013 Oct 10 |
4 |
| 24 | 24097861 | Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. | Clin Cancer Res | 2014 Feb 1 |
2 |
| 25 | 24202668 | Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. | Cancer Chemother Pharmacol | 2014 Feb |
1 |
| 26 | 24205338 | Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. | PLoS One | 2013 |
1 |
| 27 | 24210087 | Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19. | Urol Oncol | 2013 Nov |
2 |
| 28 | 24266843 | c-MET kinase inhibitors: a patent review (2011 - 2013). | Expert Opin Ther Pat | 2014 Feb |
2 |
| 29 | 24284057 | Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? | Clin Cancer Res | 2014 Feb 1 |
1 |
| 30 | 24621440 | Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. | Liver Int | 2015 Mar |
15 |
| 31 | 24700742 | Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. | Clin Cancer Res | 2014 Jun 1 |
5 |
| 32 | 24744988 | Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? | Front Oncol | 2014 |
1 |
| 33 | 24756794 | Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. | Recent Results Cancer Res | 2014 |
7 |
| 34 | 24790591 | Development of cabozantinib for the treatment of prostate cancer. | Core Evid | 2014 |
1 |
| 35 | 24827131 | A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Ann Oncol | 2014 Aug |
3 |
| 36 | 24959087 | Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. | Onco Targets Ther | 2014 |
1 |
| 37 | 25042887 | Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption. | J Cell Biochem | 2014 Nov |
7 |
| 38 | 25056653 | Cabozantinib: a review of its use in patients with medullary thyroid cancer. | Drugs | 2014 Aug |
10 |
| 39 | 25102375 | A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. | Thyroid | 2014 Oct |
3 |
| 40 | 25225437 | Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. | J Clin Oncol | 2014 Oct 20 |
2 |
| 41 | 25242168 | Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. | Int J Cancer | 2015 Apr 15 |
3 |
| 42 | 25266653 | C-MET inhibitors in the treatment of lung cancer. | Curr Treat Options Oncol | 2014 Dec |
1 |
| 43 | 25277255 | Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. | BMC Cancer | 2014 Oct 2 |
2 |
| 44 | 25321478 | Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. | Cell Death Dis | 2014 Oct 16 |
4 |
| 45 | 25351743 | Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. | Clin Cancer Res | 2015 Jan 1 |
6 |
| 46 | 25427282 | Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. | JAMA Dermatol | 2015 Feb |
3 |
| 47 | 25435367 | Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells. | Oncogene | 2015 Aug 27 |
2 |
| 48 | 25436805 | RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. | J Thorac Oncol | 2014 Nov |
2 |
| 49 | 25534569 | Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder. | Cancers (Basel) | 2014 Nov 25 |
1 |
| 50 | 25534822 | Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. | Neuro Oncol | 2015 Jul |
1 |